IPCA LABORATORIES LTD

During the earnings call held on August 14, 2026, management reported that Ipca Laboratories' domestic formulation business grew by 13% to approximately INR 1,082 crores in Q1 FY27, compared to INR 961 crores in Q1 FY26. The overall export business saw a growth of 34%, reaching around INR 603 crores. Management highlighted that the company's consolidated revenue increased by 21% to INR 2,788 crores. Despite challenges such as material price fluctuations and shipping delays, consolidated EBITDA margins improved to 22.88% from 18.39% year-on-year. Management noted that the chronic segment grew by 17.2%, while the acute segment grew by 8.9%. They also discussed the performance of their institutional and generic businesses, with significant growth reported in the institutional generic segment. Management set a goal of 14% to 16% growth for the current financial year, up from the previous guidance of 12% to 13%.

Management emphasized strong growth across various segments and improved profitability.